Melissa Tosca - Sep 29, 2023 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Role: EVP Finance
Signature: /s/ Melissa Tosca
Stock symbol: KPRX
Transactions as of: Sep 29, 2023
Transactions value $: $0
Form type: 4
Date filed: 10/3/2023, 04:49 PM
Previous filing: Mar 7, 2023
Next filing: Jun 14, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPRX	Common Stock	Award	$0	+30K	+612.24%	$0.00	34.9K	Sep 29, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KPRX	Stock Option (right to buy)	Award	$0	+60K		$0.00	60K	Sep 29, 2023	Common Stock	60K	$0.57	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to twenty-five percent (25%) of the shares immediately upon grant, and twenty-five percent (25%) on each of September 29, 2024, September 29, 2025 and September 29, 2026, subject to the reporting person's continuous service through each such vesting date.
F2	The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to twenty-five percent (25%) of the shares underlying the Option upon grant on September 29, 2023, twenty-five percent (25%) on September 29, 2024 and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

Content

Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to twenty-five percent (25%) of the shares immediately upon grant, and twenty-five percent (25%) on each of September 29, 2024, September 29, 2025 and September 29, 2026, subject to the reporting person's continuous service through each such vesting date.

The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to twenty-five percent (25%) of the shares underlying the Option upon grant on September 29, 2023, twenty-five percent (25%) on September 29, 2024 and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.